The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 30, 2025

Filed:

Oct. 05, 2020
Applicant:

University of Washington, Seattle, WA (US);

Inventors:

Brandon J. Ausk, Seattle, WA (US);

Steven Bain, Seattle, WA (US);

Ted S. Gross, Seattle, WA (US);

Assignee:

University of Washington, Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61M 5/32 (2006.01); A61B 17/34 (2006.01); A61M 5/00 (2006.01); A61M 5/19 (2006.01); A61M 5/20 (2006.01); A61M 5/315 (2006.01); A61M 5/42 (2006.01); A61M 5/46 (2006.01); A61B 17/20 (2006.01);
U.S. Cl.
CPC ...
A61M 5/3297 (2013.01); A61B 17/3403 (2013.01); A61M 5/007 (2013.01); A61M 5/19 (2013.01); A61M 5/20 (2013.01); A61M 5/31596 (2013.01); A61M 5/427 (2013.01); A61M 5/46 (2013.01); A61B 17/205 (2013.01); A61B 2017/3411 (2013.01); A61M 5/3287 (2013.01); A61M 5/3295 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01);
Abstract

Systems for treating a targeted volume of muscle tissue to inhibit heterotopic ossification (HO) employ a delivery device including a reservoir containing a neuromuscular inhibitor and an injector assembly. The injector assembly can include an arrangement of needles and an injector operable to pass the neuromuscular inhibitor from the reservoir through the needles. The injector assembly can be configured to eject predetermined aliquots of a therapeutic dose of the neuromuscular inhibitor. The injector assembly can be shaped to compliment the targeted volume of muscle tissue within a larger volume of muscle tissue. The ejection of the predetermined aliquots can result in a therapeutic distribution of the therapeutic dose of the neuromuscular inhibitor within the targeted volume of muscle tissue that is sufficient to prevent formation of an HO lesion but insufficient to induce paralysis of the larger volume of muscle tissue.


Find Patent Forward Citations

Loading…